Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | PTGIR | P43119 | 2/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 4/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3330234 | 0.90 | TACR1 (0.40) | NR1H4NOS1NOS2SLC6A4SLC6A2 | |
| SCHEMBL8303076 | 0.72 | CNR2 (0.45) | NR1H4HTT | |
| SCHEMBL15732621 | 0.72 | EPHX2 (0.40) | — | |
| SCHEMBL3423198 | 0.70 | HTT (0.55) | NR1H4HTTSLC6A4SLC6A2KCNH2 | |
| SCHEMBL3160941 | 0.69 | MT-CO2 (0.38) | SLC6A4PTGIRPTGDRKDM1A | |
| SCHEMBL31693930 | 0.69 | DPP4 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL924025 | 0.68 | TACR1 (0.49) | SLC6A4SLC6A2TACR1KCNH2 | |
| SCHEMBL11904712 | 0.68 | PTPRB (0.45) | KCNH2 | |
| SCHEMBL1143597 | 0.66 | MEN1 (0.58) | KDM1AMAOB | |
| SCHEMBL8303697 | 0.66 | HTT (0.61) | NR1H4HTTCHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, MTOR | NR1H4 1821/4885NOS1 3902/4885NOS2 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.